How to Get Repatha (Evolocumab) in Louisiana

What Is Repatha and Why Louisiana Patients Need It

Evolocumab (Repatha) is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that degrades LDL receptors on hepatocytes. Blocking PCSK9 increases the number of LDL receptors available on the liver surface, which removes more LDL-C from the bloodstream. In the landmark FOURIER trial (N=27,564), evolocumab 140 mg every 2 weeks added to statin therapy reduced LDL-C by 59% from baseline and cut the composite of cardiovascular death, MI, stroke, coronary revascularization, or unstable angina by 15% versus placebo over a median 2.2 years (hazard ratio 0.85 to 95% CI 0.79 to 0.92, P<0.001) [1].

Louisiana carries a disproportionate cardiovascular disease burden. The CDC reports that Louisiana's age-adjusted cardiovascular disease mortality rate is among the highest in the nation, making high-potency LDL-lowering therapy more than a clinical footnote for many residents [2]. Familial hypercholesterolemia (FH) affects roughly 1 in 250 people in the general population, meaning an estimated 18,000 to 20,000 Louisianans may carry a heterozygous FH mutation, and a substantial fraction remain undiagnosed [3].

Repatha carries two FDA-approved indications relevant to these patients: (1) adults with primary hyperlipidemia, including heterozygous FH, to reduce LDL-C, used as an adjunct to diet and maximally tolerated statin therapy; and (2) adults with homozygous FH, used alone or with other lipid-lowering therapies [4]. The FDA-approved prescribing information specifies these indications clearly, and Louisiana prescribers are bound by those labeling parameters [4].

How to Get a Repatha Prescription in Louisiana

A Louisiana-licensed physician, nurse practitioner, or physician assistant can prescribe Repatha after confirming the diagnosis, reviewing baseline labs, and documenting prior or current statin use. The prescribing pathway has three practical routes: in-person specialist visit, primary care physician referral, or licensed telehealth consultation.

In-person route. A cardiologist or lipidologist visit remains the most direct path because these specialists are familiar with prior authorization paperwork and routinely stock relevant supporting documentation. The American College of Cardiology/American Heart Association 2018 Cholesterol Guideline recommends considering a PCSK9 inhibitor for very-high-risk ASCVD patients whose LDL-C remains at or above 70 mg/dL despite maximally tolerated statin plus ezetimibe therapy [5]. That threshold language is precisely what commercial insurers in Louisiana use to gate prior authorization approval.

Telehealth route. Louisiana law (La. R.S. 40:1223.3) permits synchronous audio-video telehealth consultations for new and established patients, and a valid patient-physician relationship can be formed via telehealth for the purposes of issuing a prescription. Several telehealth platforms operating in Louisiana now offer PCSK9 inhibitor consultations. The prescriber must still document a confirmed indication, review labs, and verify that the patient has tried a statin (or document a medically acceptable reason for statin intolerance) before submitting a Repatha prescription.

Primary care route. Many Louisiana internists and family physicians now prescribe PCSK9 inhibitors directly, particularly for patients with established ASCVD who are already in their practice panel. The 2022 ACC Expert Consensus Decision Pathway on Non-Statin Therapies provides a stepwise algorithm that primary care clinicians can follow to determine when escalation to a PCSK9 inhibitor is appropriate [6].

Labs Required Before Repatha Is Prescribed in Louisiana

A fasting lipid panel is the single non-negotiable lab requirement. Most commercial insurers in Louisiana also request at least one prior lipid result on maximally tolerated statin therapy to confirm insufficient LDL-C lowering.

Beyond the lipid panel, prescribers frequently order the following before submitting a prior authorization:

• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST), because some insurers exclude patients with active liver disease.
• Creatine kinase (CK), particularly when documenting statin myopathy as the reason for statin intolerance.
• HbA1c or fasting glucose if the patient has metabolic risk factors, since baseline metabolic data supports the overall cardiovascular risk picture.
• TSH, because hypothyroidism causes secondary hypercholesterolemia and must be ruled out or treated before a PCSK9 inhibitor is approved.

Repatha itself has no hepatotoxicity signal in clinical trial data. In FOURIER (N=27,564), hepatic adverse events were not statistically different between the evolocumab and placebo arms [1]. The lab requirements are insurer-driven rather than pharmacologically necessary in most cases.

The FDA prescribing label for evolocumab does not mandate any pre-treatment laboratory monitoring, which underscores that the lab checklist is largely a prior authorization artifact rather than a safety prerequisite [4].

Prior Authorization in Louisiana: What Documentation Is Required

Prior authorization (PA) is required by virtually every commercial insurer operating in Louisiana, and it is the single most common delay point in getting Repatha to a patient. Louisiana Medicaid does not currently cover Repatha for FH or established ASCVD as of early 2025, so most patients rely on commercial insurance or Amgen's patient assistance program.

A standard Louisiana commercial PA submission typically requires:

1. Confirmed diagnosis (ICD-10 code E78.01 for heterozygous FH, E78.02 for homozygous FH, or I25.10 for chronic ischemic heart disease as an ASCVD marker).
2. Documentation of maximally tolerated statin therapy. The prescriber must specify the statin name, dose, and duration of use. Typical minimum duration accepted by insurers is 90 days.
3. Current fasting LDL-C on statin therapy showing LDL-C at or above the insurer's threshold (commonly 70 mg/dL for ASCVD, 100 mg/dL for FH without ASCVD).
4. Documentation of ezetimibe trial or a clinically acceptable reason for ezetimibe intolerance, because the ACC/AHA guideline positions ezetimibe as the step before PCSK9 inhibitors [5].
5. For statin-intolerant patients: documentation of at least two separate statin trials at the lowest approved dose, each resulting in myalgia or another adverse effect. CK levels and clinic notes describing symptom onset and resolution are helpful.

The National Lipid Association's PCSK9 inhibitor PA guide notes that PA approval rates improve substantially when the submission includes lab values, clinic notes, and a letter of medical necessity rather than just the prescription claim alone [7].

If the initial PA is denied, Louisiana law gives patients the right to a peer-to-peer review between the prescribing clinician and the insurer's medical director. Patients denied after peer-to-peer review may file an independent external appeal under Louisiana's Insurance Code (La. R.S. 22:2401 et seq.).

Repatha Telehealth Prescribing in Louisiana: How It Works

Telehealth prescribing of Repatha in Louisiana follows the same clinical standard as in-person prescribing. The prescriber must conduct a synchronous audio-video visit, document the patient's cardiovascular history, review uploaded lab results, confirm statin use history, and establish a diagnosis before issuing the prescription electronically.

Louisiana's telehealth statute (La. R.S. 40:1223.3) does not restrict which drug classes a telehealth provider may prescribe, provided the visit meets the standard of care. Repatha is not a controlled substance, so no DEA telemedicine waiver is needed.

Patients using a telehealth platform should prepare the following before the visit:

• A copy of their most recent fasting lipid panel (ideally within the past 6 months).
• A list of current and past statin medications with doses and reasons for any discontinuation.
• Insurance card or pharmacy benefit information.
• Any prior denial letters from a previous PA attempt.

After the telehealth visit, the prescriber submits the electronic prescription to the patient's pharmacy of choice and initiates or assists with the prior authorization. Turnaround from initial visit to PA decision is typically 10 to 21 business days, though urgent PA pathways can sometimes compress that to 72 hours for patients with recent acute coronary syndrome.

The American Telemedicine Association's clinical guidelines support synchronous video-based lipid management as clinically equivalent to in-person care for stable outpatients [8].

Repatha Pharmacies in Louisiana: Retail, Specialty, and 503A Options

Repatha requires cold-chain storage and is classified as a specialty medication by most pharmacy benefit managers (PBMs). In Louisiana, patients can obtain Repatha through three pharmacy channels.

Specialty pharmacy. Most commercial insurers in Louisiana mandate dispensing through a contracted specialty pharmacy. Amgen's SupportPlus program can connect patients to in-network specialty pharmacy options and handle benefit verification and PA coordination. Specialty pharmacies ship directly to the patient's door with temperature-controlled packaging.

Retail pharmacy. Repatha is technically dispensable at retail pharmacies with the appropriate cold-chain capability. CVS, Walgreens, and Walmart pharmacy locations in Louisiana's major metro areas (New Orleans, Baton Rouge, Shreveport, Lafayette) can dispense Repatha if the PBM permits retail dispensing for specialty biologics. Patients should call ahead to confirm cold-chain inventory.

503A compounding pharmacies. Louisiana-licensed 503A compounding pharmacies may prepare patient-specific compounded formulations for documented clinical needs, such as patients requiring a dose or concentration not available in the commercial product. A 503A pharmacy must be licensed by the Louisiana Board of Pharmacy and comply with USP Chapter 797 sterile compounding standards. The FDA's guidance on 503A pharmacy compounding specifies that compounding is permissible for identified individual patients with a valid prescription from a licensed practitioner [9]. Patients considering compounded evolocumab should verify the pharmacy's Louisiana Board of Pharmacy license and request a certificate of analysis for each batch.

Cost and patient assistance. The list price of Repatha 140 mg autoinjector is approximately $583 per pen as of 2025, making patient assistance programs practically essential for uninsured or underinsured Louisiana patients. Amgen's Repatha ACCES program offers the medication at no cost for eligible patients whose household income falls at or below 600% of the federal poverty level. Patients with commercial insurance who face high copays may also qualify for Amgen's copay card, which can reduce out-of-pocket cost to as little as $5 per month.

How Long Until You Receive Repatha in Louisiana

The total timeline from initial consultation to first injection depends on how quickly prior authorization resolves.

• Telehealth or in-person consultation: same day.
• Labs (if not already available): 1 to 3 business days for results.
• PA submission: within 1 business day of the prescriber receiving complete labs.
• PA decision (standard review): 10 to 21 business days per Louisiana Insurance Code timelines.
• Specialty pharmacy processing and shipping: 2 to 5 business days after PA approval.
• Total minimum realistic timeline: approximately 2 weeks for patients with labs already on hand and a clean PA submission.
• Total with initial denial and peer-to-peer review: 4 to 8 weeks.

Patients with very recent acute MI or unstable angina may qualify for a bridge supply through Amgen's SupportPlus program while the formal PA is pending.

Transferring a Repatha Prescription to Louisiana

Patients relocating to Louisiana with an existing Repatha prescription can transfer that prescription to a Louisiana-licensed pharmacy, subject to one limitation: because Repatha is a non-controlled specialty biologic, the prescription itself is transferable, but the PA approval does not transfer automatically. The new Louisiana-based insurer will require its own PA.

The most efficient approach is to have the new Louisiana prescriber submit a fresh PA using the patient's out-of-state medical records, prior lab results, and any prior denial or approval letters as supporting documentation. Most insurers accept out-of-state documentation as valid evidence of prior therapy.

If the patient has Medicare Part D coverage, the PA requirements remain plan-specific and do not change based on state residency. Medicare Advantage plans in Louisiana follow the same national formulary and PA rules as plans in other states, though the specific tier placement of Repatha varies by plan.

Who Can Prescribe Repatha in Louisiana

Louisiana allows the following licensed clinicians to prescribe Repatha:

Physicians (MD, DO). Any Louisiana-licensed physician in any specialty may prescribe Repatha, provided the prescription is within their scope of practice. Cardiologists, lipidologists, endocrinologists, and internal medicine physicians are the most common prescribers in practice.

Nurse practitioners (APRN). Louisiana requires APRNs to hold a collaborative practice agreement (CPA) with a supervising physician. Under a valid CPA, an APRN may prescribe Repatha. Louisiana's APRN prescriptive authority is governed by La. R.S. 37:913 et seq.

Physician assistants (PA-C). Louisiana PAs must practice under a supervision agreement. Within that agreement, PAs may prescribe Repatha if the supervising physician's scope includes cardiovascular or lipid management.

Pharmacists. Louisiana does not currently authorize pharmacist-initiated PCSK9 inhibitor prescribing under a statewide collaborative pharmacy practice agreement, so a physician or mid-level prescriber must initiate the prescription.

The 2022 ACC Expert Consensus Decision Pathway states: "Clinicians should use a systematic, stepwise approach to identify patients who are candidates for non-statin therapies, including PCSK9 inhibitors, based on risk category and LDL-C response to maximally tolerated statin therapy" [6]. That language applies equally to physicians and qualified advanced practice providers working under Louisiana's scope-of-practice rules.

Clinical Outcomes Evidence Supporting Repatha Use

The evidence base for evolocumab is among the strongest of any lipid-lowering agent approved in the past decade.

In FOURIER (N=27,564), published in the New England Journal of Medicine in 2017, patients with established ASCVD on statin therapy who received evolocumab 140 mg every 2 weeks achieved a median LDL-C of 30 mg/dL compared with 92 mg/dL in the placebo group, a 59% relative reduction [1]. The key secondary endpoint of cardiovascular death, MI, or stroke was reduced by 20% (HR 0.80 to 95% CI 0.73 to 0.88, P<0.001) [1].

In the GLAGOV trial (N=968), evolocumab produced regression of coronary atherosclerosis as measured by intravascular ultrasound. Patients receiving evolocumab had a mean change in percent atheroma volume of -0.95% versus +0.05% in the placebo group (P<0.001), confirming that deep LDL-C lowering with a PCSK9 inhibitor can reverse plaque burden [10].

For patients with heterozygous FH, the RUTHERFORD-2 trial (N=329) showed that evolocumab 140 mg every 2 weeks reduced LDL-C by 59.2% versus placebo at 12 weeks P<0.001 [11]. For homozygous FH, the TESLA Part B trial (N=50) demonstrated a 30.9% LDL-C reduction versus placebo (P<0.001), meaningful even in patients with severely impaired LDL receptor function [12].

The European Atherosclerosis Society Consensus Statement on PCSK9 inhibitors concludes that "the benefit-risk profile of PCSK9 inhibitors is favorable for patients at very high cardiovascular risk who require additional LDL-C lowering beyond what is achievable with statins and ezetimibe" [13]. Louisiana clinicians submitting PA letters of medical necessity may quote this consensus directly.

Safety data from FOURIER showed no significant excess of serious adverse events with evolocumab versus placebo over 2.2 years, including no increase in neurocognitive events, hemorrhagic stroke, or new-onset diabetes [1]. The FDA label notes that injection-site reactions occurred in 3.2% of evolocumab patients versus 3.0% placebo [4].